Wedbush Starts Harpoon Therapeutics (HARP) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- Funds sell $44bn in semiconductors on AI concerns
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
Canaccord Genuity Starts Harpoon Therapeutics (HARP) at Buy
March 5, 2019 6:16 AM ESTCanaccord Genuity analyst Arlinda Lee initiates coverage on Harpoon Therapeutics (NASDAQ: HARP) with a Buy rating and a price target of $24.00.
For an analyst ratings summary and ratings history on Harpoon Therapeutics click here. For more ratings news on Harpoon Therapeutics click here.
Shares of Harpoon Therapeutics closed at $17.01 yesterday.
... More